Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Wet Age-related Macular Degeneration (wAMD)

Interventions

DRUG

AL-001

Administered via suprachoroidal space injection.

Trial Locations (1)

Chinese Academy of Medical Sciences & Peking Union Hospital, Beijing

All Listed Sponsors

lead

Beijing Anlong Biopharmaceutical Co., Ltd.

INDUSTRY

NCT06707753 - Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD | Biotech Hunter | Biotech Hunter